Literature DB >> 35449753

Macroglossia in a Patient With Recurrent Multiple Myeloma.

Muhammad Wasif Saif1, Chris H Takimoto1.   

Abstract

Entities:  

Year:  2000        PMID： 35449753      PMCID： PMC9020445     

Source DB:  PubMed          Journal:  Consultant        ISSN： 0010-7069


× No keyword cloud information.
  7 in total

Review 1.  Primary salivary gland amyloidosis causing sicca syndrome.

Authors:  D Myssiorek; A Alvi; T Bhuiya
Journal:  Ann Otol Rhinol Laryngol       Date:  1992-06       Impact factor: 1.547

2.  Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only.

Authors:  M Skinner; J Anderson; R Simms; R Falk; M Wang; C Libbey; L A Jones; A S Cohen
Journal:  Am J Med       Date:  1996-03       Impact factor: 4.965

Review 3.  Clinical aspects of multiple myeloma and related disorders including amyloidosis.

Authors:  R A Kyle
Journal:  Pathol Biol (Paris)       Date:  1999-02

4.  A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine.

Authors:  R A Kyle; M A Gertz; P R Greipp; T E Witzig; J A Lust; M Q Lacy; T M Therneau
Journal:  N Engl J Med       Date:  1997-04-24       Impact factor: 91.245

Review 5.  Primary systemic amyloidosis--a diagnostic primer.

Authors:  M A Gertz; R A Kyle
Journal:  Mayo Clin Proc       Date:  1989-12       Impact factor: 7.616

6.  Labial salivary gland biopsy is a reliable test for the diagnosis of primary and secondary amyloidosis. A prospective clinical and immunohistologic study in 59 patients.

Authors:  E Hachulla; A Janin; R M Flipo; R Saïle; T Facon; D Bataille; P Vanhille; P Y Hatron; B Devulder; B Duquesnoy
Journal:  Arthritis Rheum       Date:  1993-05

7.  Localized amyloidosis of the head and neck and upper aerodigestive and lower respiratory tracts.

Authors:  G T Simpson; M S Strong; M Skinner; A S Cohen
Journal:  Ann Otol Rhinol Laryngol       Date:  1984 Jul-Aug       Impact factor: 1.547
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.